Cost of human immunodeficiency virus infection in Italy, 2007&ndash;2009: effective and expensive, are the new drugs worthwhile? | Zendy

Giuliano Rizzardini | Zendy; Restelli | Zendy; Bonfanti | Zendy; Porazzi | Zendy; Elena Ricci | Zendy; Foglia | Zendy; Davide Croce | Zendy; Carenzi | Zendy

Open Access

Cost of human immunodeficiency virus infection in Italy, 2007–2009: effective and expensive, are the new drugs worthwhile?

Author(s) -

Giuliano Rizzardini,

Restelli,

Bonfanti,

Porazzi,

Elena Ricci,

Foglia,

Davide Croce,

Carenzi

Publication year - 2012

Publication title -

clinicoeconomics and outcomes research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.591

H-Index - 27

ISSN - 1178-6981

DOI - 10.2147/ceor.s35194

Subject(s) - medicine , coinfection , hepatitis c virus , observational study , retrospective cohort study , hepatitis c , human immunodeficiency virus (hiv) , emergency medicine , pediatrics , immunology , virus

In recent years, the increased efficacy and effectiveness of antiretroviral treatment has led to longer survival of patients infected with human immunodeficiency virus (HIV), but has also raised the question of what happens to consumption of resources. Early highly active antiretroviral treatment (HAART), management of hepatitis C virus (HCV) coinfection, and expensive newly marketed drugs may affect the economic sustainability of treatment from the point of view of the National Healthcare Services. The present study aimed to provide information on the economic burden of HIV-positive patients resident in the Lombardy region using a three-year time horizon.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research